A tumor vasculature targeted liposome delivery system for combretastatin A4: Design, characterization, and in vitro evaluation
10.1208/pt070232
Crossref journal-article
Springer Science and Business Media LLC
AAPS PharmSciTech (297)
Bibliography

Nallamothu, R., Wood, G. C., Pattillo, C. B., Scott, R. C., Kiani, M. F., Moore, B. M., & Thoma, L. A. (2006). A tumor vasculature targeted liposome delivery system for combretastatin A4: Design, characterization, and in vitro evaluation. AAPS PharmSciTech, 7(2), E7–E16.

Authors 7
  1. Ramakrishna Nallamothu (first)
  2. George C. Wood (additional)
  3. Christopher B. Pattillo (additional)
  4. Robert C. Scott (additional)
  5. Mohammad F. Kiani (additional)
  6. Bob M. Moore (additional)
  7. Laura A. Thoma (additional)
References 32 Referenced 61
  1. Lasic DD, Papahadjopoulos D. Medical Applications of Liposomes. Amsterdam, The Netherlands: Elsevier; 1998. / Medical Applications of Liposomes by DD Lasic (1998)
  2. Forssen EA, Coulter DM, Proffitt RT. Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors. Cancer Res. 1992; 52: 3255–3261. / Cancer Res. by EA Forssen (1992)
  3. Park JW, Hong K, Kirpotin DB, Meyer O, Papahadjopoulos D, Benz CC. Anti-HER2 immunoliposomes for targeted therapy of human tumors. Cancer Lett. 1997; 118: 153–160. (10.1016/S0304-3835(97)00326-1) / Cancer Lett. by JW Park (1997)
  4. Stephenson SM, Low PS, Lee RJ. Folate receptor-mediated targeting of liposomal drugs to cancer cells. Methods Enzymol. 2004; 387: 33–50. (10.1016/S0076-6879(04)87003-4) / Methods Enzymol. by SM Stephenson (2006)
  5. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res. 1997; 57: 1829–1834. / Cancer Res. by GG Dark (1997)
  6. Young SL, Chaplin DJ. Combretastatin A4 phosphate: background and current clinical status. Expert Opin Investig Drugs. 2004; 13: 1171–1182. (10.1517/13543784.13.9.1171) / Expert Opin Investig Drugs. by SL Young (2006)
  7. Hynes RO. A reevaluation of integrins as regulators of angiogenesis. Nat Med. 2002; 8: 918–921. (10.1038/nm0902-918) / Nat Med. by RO Hynes (2002)
  8. Kumar CC, Armstrong L, Yin Z, et al. Targeting integrins alpha v beta 3 and alpha v beta 5 for blocking tumor-induced angiogenesis. Adv Exp Med Biol. 2000; 476: 169–180. (10.1007/978-1-4615-4221-6_14) / Adv Exp Med Biol. by CC Kumar (2000)
  9. Haubner R, Gratias R, Diefenbach B, Goodman SL, Jonczyk A, Kessler H. Structural and functional aspects of RGD-containing cyclic pentapeptides as highly potent and selective integrin alpha v beta 3 antagonists. J Am Chem Soc. 1996; 118: 7461–7472. (10.1021/ja9603721) / J Am Chem Soc. by R Haubner (1996)
  10. Pattillo CB, Sari-Sarraf F, Nallamothu R, Moore BM, Wood GC, Kiani MF. Targeting of the antivascular drug combretastatin to irradiated tumors results in tumor growth delay. Pharm Res. 2005; 22: 1117–1120. (10.1007/s11095-005-5646-0) / Pharm Res. by CB Pattillo (2005)
  11. Pettit GR, Singh SB, Boyd MR, et al. Antineoplastic agents. 291. Isolation and synthesis of combretastatins A-4, A-5, and A-6(1a). J Med Chem. 1995; 38: 1666–1672. (10.1021/jm00010a011) / J Med Chem. by GR Pettit (1995)
  12. Hope MJ, Bally MB, Webb G, Cullis PR. Production of large unilamellar vesicles by a rapid extrusion procedure: characterization of size distribution, trapped volume and ability to maintain a membrane potential. Biochim Biophys Acta. 1985; 812: 55–65. (10.1016/0005-2736(85)90521-8) / Biochim Biophys Acta. by MJ Hope (1985)
  13. New RRC, Black CDV, Parker RJ, Puri A, Scherphof GL. Liposomes in biological systems. In: New RRC, ed. Liposomes: A Practical Approach. Oxford, UK: IRL Press Ltd; 1993: 221–252. / Liposomes: A Practical Approach by RRC New (1993)
  14. Prabhakarpandian B, Goetz DJ, Swerlick RA, Chen X, Kiani MF. Expression and functional significance of E-selectin on cultured endothelial cells in response to ionizing radiation. Microcirculation. 2001; 8: 355–364. (10.1038/sj.mn.7800105) / Microcirculation. by B Prabhakarpandian (2001)
  15. Gabizon A, Chemla M, Tzemach D, Horowitz AT, Goren D. Liposome longevity and stability in circulation: effects on the in vivo delivery to tumors and therapeutic efficacy of encapsulated anthracyclines. J Drug Target. 1996; 3: 391–398. (10.3109/10611869608996830) / J Drug Target. by A Gabizon (1996)
  16. Kirby C, Clarke J, Gregoriadis G. Effect of the cholesterol content of small unilamellar liposomes on their stability in vivo and in vitro. Biochem J. 1980; 186: 591–598. (10.1042/bj1860591) / Biochem J. by C Kirby (1980)
  17. Semple SC, Chonn A, Cullis PR. Influence of cholesterol on the association of plasma proteins with liposomes. Biochemistry. 1996; 35: 2521–2525. (10.1021/bi950414i) / Biochemistry. by SC Semple (1996)
  18. Torchilin VP, Omelyanenko VG, Papisov MI, et al. Poly(ethylene glycol) on the liposome surface: on the mechanism of polymer-coated liposome longevity. Biochim Biophys Acta. 1994; 1195: 11–20. (10.1016/0005-2736(94)90003-5) / Biochim Biophys Acta. by VP Torchilin (1994)
  19. Hansen CB, Kao GY, Moase EH, Zalipsky S, Allen TM. Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures. Biochim Biophys Acta. 1995; 1239: 133–144. (10.1016/0005-2736(95)00138-S) / Biochim Biophys Acta. by CB Hansen (1995)
  20. Martin FJ, Papahadjopoulos D. Irreversible coupling of immunoglobulin fragments to preformed vesicles: an improved method for liposome targeting. J Biol Chem. 1982; 257: 286–288. (10.1016/S0021-9258(19)68359-6) / J Biol Chem. by FJ Martin (1982)
  21. Allen TM, Brandeis E, Hansen CB, Kao GY, Zalipsky S. A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. Biochim Biophys Acta. 1995; 1237: 99–108. (10.1016/0005-2736(95)00085-H) / Biochim Biophys Acta. by TM Allen (1995)
  22. Maurer N, Fenske DB, Cullis PR. Developments in liposomal drug delivery systems. Expert Opin Biol Ther. 2001; 1: 923–947. (10.1517/14712598.1.6.923) / Expert Opin Biol Ther. by N Maurer (2001)
  23. Rouser G, Fkeischer S, Yamamoto A. Two dimensional thin layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots. Lipids. 1970; 5: 494–496. (10.1007/BF02531316) / Lipids. by G Rouser (1970)
  24. Kawahara K, Sekiguchi A, Kiyoki E, et al. Effect of TRX-liposomes size on their prolonged circulation in rats. Chem Pharm Bull (Tokyo). 2003; 51: 336–338. (10.1248/cpb.51.336) / Chem Pharm Bull (Tokyo) by K Kawahara (2003)
  25. Bredehorst R, Ligler FS, Kusterbeck AW, Chang EL, Gaber BP. Vogel CW. Effect of covalent attachment of immunoglobulin fragments on liposomal integrity. Biochemistry. 1986; 25: 5693–5698. (10.1021/bi00367a052) / Biochemistry. by R Bredehorst (1986)
  26. Spragg DD, Alford DR, Greferath R, et al. Immunotargeting of liposomes to activated vascular endothelial cells: a strategy for site-selective delivery in the cardiovascular system. Proc Natl Acad Sci USA. 1997; 94: 8795–8800. (10.1073/pnas.94.16.8795) / Proc Natl Acad Sci USA. by DD Spragg (1997)
  27. Cheresh DA. Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor. Proc Natl Acad Sci USA. 1987; 84: 6471–6475. (10.1073/pnas.84.18.6471) / Proc Natl Acad Sci USA. by DA Cheresh (1987)
  28. Czyz M, Cierniewski CS. Selective Sp1 and Sp3 binding is crucial for activity of the integrin alpha v promoter in cultured endothelial cells. Eur J Biochem. 1999; 265: 638–644. (10.1046/j.1432-1327.1999.00754.x) / Eur J Biochem. by M Czyz (1999)
  29. Koning GA, Morselt HW, Velinova MJ, et al. Selective transfer of a lipophilic prodrug of 5-fluorodeoxyuridine from immunoliposomes to colon cancer cells. Biochim Biophys Acta. 1999; 1420: 153–167. (10.1016/S0005-2736(99)00091-7) / Biochim Biophys Acta. by GA Koning (1999)
  30. Goren D, Horowitz AT, Zalipsky S, Woodle MC, Yarden Y, Gabizon A. Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies. Br J Cancer: 1996; 74: 1749–1756. (10.1038/bjc.1996.625) / Br J Cancer by D Goren (1996)
  31. Kirpotin D, Park JW, Hong K, et al. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry. 1997; 36: 66–75. (10.1021/bi962148u) / Biochemistry. by D Kirpotin (1997)
  32. Yuan F, Dellian M, Fukumura D, et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 1995; 55: 3752–3756. / Cancer Res. by F Yuan (1995)
Dates
Type When
Created 18 years, 9 months ago (Nov. 3, 2006, 3:44 p.m.)
Deposited 4 years ago (Aug. 4, 2021, 5:43 a.m.)
Indexed 4 weeks, 2 days ago (Aug. 2, 2025, 12:47 a.m.)
Issued 19 years, 3 months ago (June 1, 2006)
Published 19 years, 3 months ago (June 1, 2006)
Published Print 19 years, 3 months ago (June 1, 2006)
Funders 0

None

@article{Nallamothu_2006, title={A tumor vasculature targeted liposome delivery system for combretastatin A4: Design, characterization, and in vitro evaluation}, volume={7}, ISSN={1530-9932}, url={http://dx.doi.org/10.1208/pt070232}, DOI={10.1208/pt070232}, number={2}, journal={AAPS PharmSciTech}, publisher={Springer Science and Business Media LLC}, author={Nallamothu, Ramakrishna and Wood, George C. and Pattillo, Christopher B. and Scott, Robert C. and Kiani, Mohammad F. and Moore, Bob M. and Thoma, Laura A.}, year={2006}, month=jun, pages={E7–E16} }